265 related articles for article (PubMed ID: 36276066)
21. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
Qin SY; Zhang AQ; Zhang XZ
Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
[TBL] [Abstract][Full Text] [Related]
22. Nanomedicines for targeted pulmonary delivery: receptor-mediated strategy and alternatives.
Wang W; Zhong Z; Huang Z; Hiew TN; Huang Y; Wu C; Pan X
Nanoscale; 2024 Feb; 16(6):2820-2833. PubMed ID: 38289362
[TBL] [Abstract][Full Text] [Related]
23. Targeted delivery and enhanced uptake of chemo-photodynamic nanomedicine for melanoma treatment.
Huang X; Mu N; Ding Y; Lam HW; Yue L; Gao C; Chen T; Yuan Z; Wang R
Acta Biomater; 2022 Jul; 147():356-365. PubMed ID: 35577046
[TBL] [Abstract][Full Text] [Related]
24. Advanced nanomedicines for the regulation of cancer metabolism.
Yang J; Zhao Y; Zhou Y; Wei X; Wang H; Si N; Yang J; Zhao Q; Bian B; Zhao H
Biomaterials; 2022 Jul; 286():121565. PubMed ID: 35576808
[TBL] [Abstract][Full Text] [Related]
25. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
Kwon S; Ko H; You DG; Kataoka K; Park JH
Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
[TBL] [Abstract][Full Text] [Related]
26. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy.
Hussain Z; Rahim MA; Jan N; Shah H; Rawas-Qalaji M; Khan S; Sohail M; Thu HE; Ramli NA; Sarfraz RM; Abourehab MAS
J Control Release; 2021 Jul; 335():130-157. PubMed ID: 34015400
[TBL] [Abstract][Full Text] [Related]
27. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
28. Polymer nanomedicines based on micelle-forming amphiphilic or water-soluble polymer-doxorubicin conjugates: Comparative study of in vitro and in vivo properties related to the polymer carrier structure, composition, and hydrodynamic properties.
Braunová A; Chytil P; Laga R; Šírová M; Machová D; Parnica J; Říhová B; Janoušková O; Etrych T
J Control Release; 2020 May; 321():718-733. PubMed ID: 32142741
[TBL] [Abstract][Full Text] [Related]
29. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
[TBL] [Abstract][Full Text] [Related]
30. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
31. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages.
Yu W; Hu C; Gao H
Adv Drug Deliv Rev; 2021 Nov; 178():113909. PubMed ID: 34352354
[TBL] [Abstract][Full Text] [Related]
32. Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect.
Zhang S; Zhang S; Luo S; Tang P; Wan M; Wu D; Gao W
J Nanobiotechnology; 2022 Jun; 20(1):287. PubMed ID: 35710426
[TBL] [Abstract][Full Text] [Related]
33. Carrier-Free Nanomedicine for Cancer Immunotherapy.
Fu Y; Bian X; Li P; Huang Y; Li C
J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
[TBL] [Abstract][Full Text] [Related]
34. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
He Q; Shi J
Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
[TBL] [Abstract][Full Text] [Related]
35. Effect of high intensity focused ultrasound (HIFU) in conjunction with a nanomedicines-microbubble complex for enhanced drug delivery.
Han H; Lee H; Kim K; Kim H
J Control Release; 2017 Nov; 266():75-86. PubMed ID: 28928042
[TBL] [Abstract][Full Text] [Related]
36. Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy.
van den Broek SL; Shalgunov V; Herth MM
Biomater Adv; 2022 Oct; 141():213125. PubMed ID: 36182833
[TBL] [Abstract][Full Text] [Related]
37. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.
Alaarg A; Senders ML; Varela-Moreira A; Pérez-Medina C; Zhao Y; Tang J; Fay F; Reiner T; Fayad ZA; Hennink WE; Metselaar JM; Mulder WJM; Storm G
J Control Release; 2017 Sep; 262():47-57. PubMed ID: 28700897
[TBL] [Abstract][Full Text] [Related]
38. Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs.
Sabit H; Abdel-Hakeem M; Shoala T; Abdel-Ghany S; Abdel-Latif MM; Almulhim J; Mansy M
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015192
[TBL] [Abstract][Full Text] [Related]
39. Targeting tumor associated macrophages: The new challenge for nanomedicine.
Andón FT; Digifico E; Maeda A; Erreni M; Mantovani A; Alonso MJ; Allavena P
Semin Immunol; 2017 Dec; 34():103-113. PubMed ID: 28941641
[TBL] [Abstract][Full Text] [Related]
40. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
